Treatment-naive adults without cirrhosis

For treatment-naive adults with hepatitis C who do not have cirrhosis, and regardless of HCV genotype, use:

The above regimens are pangenotypic (effective for genotypes 1 to 6) and are considered equally effective. The choice is largely driven by patient preference for duration and number of tablets per dose.

Genotype-specific direct-acting antiviral regimens are also available (eg ledipasvir+sofosbuvir, elbasvir+grazoprevir); however, they have a limited role in the management of hepatitis C in Australia. For further information, see the Australian recommendations for the management of hepatitis C virus infection: A consensus statement, available online.